Kuros Biosciences AG (0RHR.L)

CHF 20.55

(1.23%)

Market Cap (In CHF)

775.44 Million

Revenue (In CHF)

33.56 Million

Net Income (In CHF)

-13.72 Million

Avg. Volume

16.95 Thousand

Currency
CHF
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.33-20.75
PE
-
EPS
-
Beta Value
0.758
ISIN
CH0325814116
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Christopher T. Fair
Employee Count
-
Website
https://www.kuros.ch
Ipo Date
2023-05-24
Details
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.